UNSPSC 51292028: Talopram hydrochloride

This classification denotes an antidepressant agent with the molecular formula C20H25NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0X97008FCC, chemically known as 3,3-dimethyl-1-(3-methylaminopropyl)-1-phenylphthalene but more generally known as talopram hydrochloride, which bears US NIH Compound Identifier 23573. Most nations, for tariff and trade purposes, schedule talopram hydrochloride under HS 29329985 and SITC 51569. As of Q4 2014, TALOPRAM HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

Talopram hydrochloride bears US NLM identifiers UMLS ID C2348647 and NCI Concept Code C73810. SMILES: CC1(C2CCCCC2C(O1)(CCCNC)C3CCCCC3)C.CL.

UNSPSC 51292028 Talopram hydrochloride is a Commodity code that in recent state and local procurement activity describes selective serotonin reuptake inhibitor (SSRI) medications and related pharmaceutical products procured through coordinated purchasing vehicles and direct government health and pharmacy benefit programs. However, the recent opportunities tagged under this code show significant scope mismatch: the three most recent solicitations name naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products—none of which are talopram hydrochloride specifically. The code shows little relevant recent activity aligned to its nominal pharmaceutical substance scope, suggesting either misclassification in the posting systems or use of the code as a catch-all for broader pharmaceutical procurement categories.

Issuing bodies soliciting under or near this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across participating jurisdictions including Oregon). Recent solicitations span Florida, Texas, and Minnesota, with geographic spread across the upper Midwest and Southeast. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (due July 26, 2023); Texas HHS's RFI on direct-to-manufacturer prescription programs posted April 3, 2026; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, and contract effectiveness July 1, 2026. Vendors pursuing activity in this taxonomy should verify code alignment with actual commodity scope before investing in response preparation, as the nominal code description and recent posting practices do not align consistently.